BioWorld

July 7, 2009

Ikaria, BioLineRx Enter Cardiac Licensing Deal Worth $282.5M

Ikaria Holdings Inc. has entered a deal worth a potential $282.5 million with Jerusalem-based BioLineRx Ltd. to license a cardiac remodeling product. (BioWorld Today) Read More

OxiGene Frees up Cash, Product Rights in Low-Priced JV Buyout

Spectrum Spirals on Zevalin Complete Response Letter

FDA Query Gives Confidence to Protalix for Gaucher Drug

Novacta Gets $21M Backing for Antibiotics Development

NIH Finalizes Embryonic Stem Cell Funding Guidelines

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...